| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diagnostic Imaging | 16 | 2023 | 1162 | 2.470 |
Why?
|
| Radiology | 9 | 2021 | 434 | 2.140 |
Why?
|
| Tomography, X-Ray Computed | 27 | 2022 | 7551 | 1.900 |
Why?
|
| Multimodal Imaging | 5 | 2019 | 550 | 1.700 |
Why?
|
| Burnout, Professional | 3 | 2020 | 205 | 1.600 |
Why?
|
| Magnetic Resonance Imaging | 27 | 2023 | 7702 | 1.370 |
Why?
|
| Radiologists | 7 | 2022 | 163 | 1.300 |
Why?
|
| Ovarian Neoplasms | 9 | 2023 | 4638 | 1.260 |
Why?
|
| Kidney Neoplasms | 9 | 2023 | 3022 | 1.180 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 600 | 1.020 |
Why?
|
| Positron Emission Tomography Computed Tomography | 6 | 2021 | 833 | 0.910 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2023 | 2326 | 0.910 |
Why?
|
| Hernia, Diaphragmatic | 2 | 2013 | 121 | 0.880 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2021 | 25 | 0.820 |
Why?
|
| Angiomyolipoma | 1 | 2021 | 31 | 0.810 |
Why?
|
| Positron-Emission Tomography | 9 | 2021 | 2173 | 0.800 |
Why?
|
| Faculty | 2 | 2020 | 130 | 0.780 |
Why?
|
| Contrast Media | 9 | 2020 | 1472 | 0.770 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2021 | 1226 | 0.750 |
Why?
|
| Liver Neoplasms | 5 | 2020 | 4557 | 0.740 |
Why?
|
| Tuberous Sclerosis | 1 | 2021 | 136 | 0.730 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 223 | 0.710 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2020 | 39 | 0.710 |
Why?
|
| Carcinoid Tumor | 2 | 2013 | 280 | 0.680 |
Why?
|
| Meningitis | 2 | 2010 | 112 | 0.670 |
Why?
|
| Teratoma | 1 | 2021 | 236 | 0.660 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 297 | 0.660 |
Why?
|
| Diagnosis, Differential | 16 | 2021 | 4744 | 0.660 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 245 | 0.650 |
Why?
|
| Esophagectomy | 2 | 2013 | 911 | 0.650 |
Why?
|
| Humans | 92 | 2023 | 261506 | 0.640 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 328 | 0.620 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2019 | 109 | 0.620 |
Why?
|
| Sarcoidosis | 1 | 2018 | 112 | 0.600 |
Why?
|
| Rectal Neoplasms | 3 | 2019 | 1202 | 0.590 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2018 | 115 | 0.590 |
Why?
|
| Societies, Medical | 10 | 2023 | 1335 | 0.590 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 568 | 0.570 |
Why?
|
| Medical Records | 1 | 2017 | 415 | 0.550 |
Why?
|
| Leadership | 1 | 2019 | 254 | 0.550 |
Why?
|
| Education, Medical | 1 | 2020 | 331 | 0.540 |
Why?
|
| Ultrasonography | 6 | 2022 | 1863 | 0.530 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2020 | 172 | 0.530 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 672 | 0.520 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2020 | 223 | 0.520 |
Why?
|
| Students, Medical | 1 | 2020 | 399 | 0.490 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2018 | 2027 | 0.490 |
Why?
|
| Renal Insufficiency | 2 | 2021 | 321 | 0.490 |
Why?
|
| Multidetector Computed Tomography | 2 | 2014 | 150 | 0.460 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 993 | 0.450 |
Why?
|
| Sarcoma | 2 | 2021 | 1725 | 0.450 |
Why?
|
| Urogenital System | 1 | 2013 | 59 | 0.440 |
Why?
|
| Pelvis | 3 | 2022 | 362 | 0.440 |
Why?
|
| Calcinosis | 1 | 2016 | 423 | 0.440 |
Why?
|
| Spinal Puncture | 2 | 2010 | 63 | 0.440 |
Why?
|
| Digestive System | 1 | 2013 | 114 | 0.440 |
Why?
|
| Genital Neoplasms, Female | 4 | 2021 | 735 | 0.430 |
Why?
|
| Blood Vessels | 2 | 2013 | 217 | 0.430 |
Why?
|
| Abdomen, Acute | 1 | 2012 | 36 | 0.410 |
Why?
|
| Carcinoma, Medullary | 1 | 2013 | 248 | 0.410 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 882 | 0.400 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2013 | 361 | 0.380 |
Why?
|
| Forecasting | 1 | 2013 | 694 | 0.380 |
Why?
|
| Hemifacial Spasm | 1 | 2010 | 21 | 0.380 |
Why?
|
| Portal Vein | 1 | 2012 | 355 | 0.370 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1350 | 0.360 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 584 | 0.360 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 821 | 0.350 |
Why?
|
| Intracranial Thrombosis | 1 | 2009 | 17 | 0.340 |
Why?
|
| Medical Oncology | 2 | 2021 | 1423 | 0.340 |
Why?
|
| Precision Medicine | 1 | 2017 | 1154 | 0.340 |
Why?
|
| Defensive Medicine | 1 | 2008 | 8 | 0.330 |
Why?
|
| Anus Neoplasms | 3 | 2023 | 411 | 0.330 |
Why?
|
| Liver Abscess | 1 | 2008 | 36 | 0.330 |
Why?
|
| Lymphoma | 2 | 2016 | 1467 | 0.330 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 5112 | 0.330 |
Why?
|
| Radiotherapy | 2 | 2013 | 1824 | 0.330 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 95 | 0.320 |
Why?
|
| Bronchial Neoplasms | 1 | 2008 | 79 | 0.320 |
Why?
|
| Radiology Information Systems | 2 | 2020 | 114 | 0.310 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 551 | 0.310 |
Why?
|
| Chest Pain | 1 | 2008 | 155 | 0.310 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 14289 | 0.310 |
Why?
|
| Female | 30 | 2023 | 141928 | 0.300 |
Why?
|
| Gastrostomy | 1 | 2008 | 180 | 0.290 |
Why?
|
| Sensitivity and Specificity | 8 | 2019 | 4971 | 0.290 |
Why?
|
| Prevalence | 3 | 2020 | 3260 | 0.290 |
Why?
|
| Vena Cava, Inferior | 2 | 2021 | 190 | 0.290 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2015 | 592 | 0.280 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2021 | 489 | 0.280 |
Why?
|
| Radiographic Image Enhancement | 2 | 2020 | 402 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10035 | 0.280 |
Why?
|
| Pancreatic Neoplasms | 4 | 2021 | 5061 | 0.280 |
Why?
|
| Cerebellar Neoplasms | 1 | 2010 | 434 | 0.270 |
Why?
|
| Aged | 15 | 2021 | 70117 | 0.260 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 384 | 0.260 |
Why?
|
| Adult | 16 | 2022 | 77950 | 0.260 |
Why?
|
| Evidence-Based Medicine | 5 | 2022 | 1085 | 0.260 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 13658 | 0.260 |
Why?
|
| Molecular Probe Techniques | 2 | 2015 | 46 | 0.250 |
Why?
|
| Molecular Probes | 2 | 2015 | 72 | 0.250 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 5767 | 0.240 |
Why?
|
| Middle Aged | 16 | 2020 | 86204 | 0.220 |
Why?
|
| Molecular Imaging | 2 | 2015 | 185 | 0.220 |
Why?
|
| Retrospective Studies | 11 | 2020 | 37905 | 0.220 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 1866 | 0.220 |
Why?
|
| Pyelonephritis | 1 | 2022 | 39 | 0.220 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2023 | 82 | 0.220 |
Why?
|
| Population Surveillance | 2 | 2018 | 627 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 332 | 0.210 |
Why?
|
| Algorithms | 1 | 2013 | 3890 | 0.210 |
Why?
|
| Young Adult | 6 | 2020 | 21445 | 0.210 |
Why?
|
| Radiography, Abdominal | 1 | 2022 | 120 | 0.210 |
Why?
|
| United States | 9 | 2023 | 15433 | 0.210 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2022 | 77 | 0.200 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2021 | 35 | 0.200 |
Why?
|
| Watchful Waiting | 2 | 2022 | 289 | 0.200 |
Why?
|
| Adrenal Gland Diseases | 1 | 2021 | 72 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2013 | 5542 | 0.190 |
Why?
|
| Male | 17 | 2022 | 123000 | 0.190 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2021 | 108 | 0.190 |
Why?
|
| Abdomen | 3 | 2022 | 332 | 0.190 |
Why?
|
| Vaginal Neoplasms | 1 | 2021 | 152 | 0.180 |
Why?
|
| Cholestasis | 1 | 2022 | 203 | 0.180 |
Why?
|
| Adrenocortical Adenoma | 1 | 2020 | 22 | 0.180 |
Why?
|
| Cysts | 1 | 2021 | 197 | 0.180 |
Why?
|
| Peritoneum | 1 | 2020 | 150 | 0.180 |
Why?
|
| Hematuria | 1 | 2020 | 85 | 0.180 |
Why?
|
| Self-Directed Learning as Topic | 1 | 2019 | 2 | 0.180 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 3168 | 0.180 |
Why?
|
| Neoplasms | 5 | 2023 | 15193 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2021 | 479 | 0.170 |
Why?
|
| Depersonalization | 1 | 2019 | 15 | 0.170 |
Why?
|
| Adolescent | 6 | 2020 | 31252 | 0.170 |
Why?
|
| Work-Life Balance | 1 | 2019 | 11 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2020 | 122 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 3981 | 0.170 |
Why?
|
| United Kingdom | 2 | 2009 | 257 | 0.160 |
Why?
|
| Spleen | 1 | 2020 | 676 | 0.160 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 321 | 0.160 |
Why?
|
| Radiology Department, Hospital | 1 | 2019 | 52 | 0.160 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2017 | 7 | 0.160 |
Why?
|
| Occupational Health | 1 | 2018 | 95 | 0.160 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 374 | 0.150 |
Why?
|
| Prognosis | 5 | 2023 | 21713 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 354 | 0.150 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 4844 | 0.150 |
Why?
|
| Radiopharmaceuticals | 2 | 2020 | 1301 | 0.150 |
Why?
|
| Imatinib Mesylate | 1 | 2021 | 1665 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2019 | 414 | 0.150 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 251 | 0.150 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 5687 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2021 | 712 | 0.140 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2017 | 54 | 0.140 |
Why?
|
| Mesentery | 1 | 2016 | 72 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 29902 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 17523 | 0.140 |
Why?
|
| Mesenchymoma | 1 | 2015 | 14 | 0.130 |
Why?
|
| Intestinal Diseases | 1 | 2016 | 121 | 0.130 |
Why?
|
| Brain | 1 | 2008 | 4113 | 0.130 |
Why?
|
| Liver | 2 | 2018 | 2961 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 860 | 0.120 |
Why?
|
| Renal Veins | 1 | 2014 | 56 | 0.120 |
Why?
|
| Health Promotion | 1 | 2018 | 502 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2330 | 0.120 |
Why?
|
| Pancreatic Diseases | 1 | 2015 | 108 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3251 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2015 | 209 | 0.120 |
Why?
|
| Nephrectomy | 2 | 2019 | 779 | 0.120 |
Why?
|
| Triiodobenzoic Acids | 1 | 2013 | 68 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 6009 | 0.110 |
Why?
|
| Incidence | 2 | 2013 | 5673 | 0.110 |
Why?
|
| Biomarkers | 2 | 2015 | 5047 | 0.110 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 221 | 0.110 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 341 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4314 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 660 | 0.110 |
Why?
|
| Meningocele | 1 | 2012 | 20 | 0.100 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 234 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2020 | 32848 | 0.100 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2013 | 192 | 0.100 |
Why?
|
| Genomics | 2 | 2020 | 2738 | 0.100 |
Why?
|
| Image Enhancement | 1 | 2015 | 561 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 661 | 0.100 |
Why?
|
| Cerebellopontine Angle | 1 | 2010 | 12 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 4367 | 0.100 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 545 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 363 | 0.090 |
Why?
|
| Anal Canal | 2 | 2023 | 238 | 0.090 |
Why?
|
| Incidental Findings | 1 | 2012 | 272 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 1509 | 0.090 |
Why?
|
| Biopsy | 1 | 2017 | 3443 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2403 | 0.090 |
Why?
|
| Proteomics | 1 | 2015 | 1380 | 0.080 |
Why?
|
| Intracranial Pressure | 1 | 2009 | 180 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 15862 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2483 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2023 | 14889 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2008 | 232 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1756 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 925 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5539 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 589 | 0.070 |
Why?
|
| Nervous System Malformations | 1 | 2008 | 133 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.070 |
Why?
|
| Thorax | 2 | 2021 | 213 | 0.070 |
Why?
|
| Radiography, Interventional | 1 | 2008 | 305 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2359 | 0.070 |
Why?
|
| Patients | 1 | 2008 | 245 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 5437 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 2008 | 474 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2012 | 1411 | 0.060 |
Why?
|
| Mutation | 2 | 2021 | 15179 | 0.060 |
Why?
|
| Toes | 1 | 2023 | 46 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 671 | 0.060 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 10331 | 0.050 |
Why?
|
| Liver Cirrhosis | 2 | 2022 | 941 | 0.050 |
Why?
|
| Bile Ducts | 1 | 2022 | 113 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 2594 | 0.050 |
Why?
|
| Decision Making | 1 | 2009 | 1287 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2021 | 122 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 7789 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 1375 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2015 | 938 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2020 | 77 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2020 | 47 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2021 | 176 | 0.050 |
Why?
|
| Injections | 1 | 2020 | 285 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2020 | 99 | 0.040 |
Why?
|
| Time Factors | 1 | 2013 | 12926 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1021 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2013 | 12873 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 457 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2022 | 1014 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 3976 | 0.040 |
Why?
|
| Rectum | 1 | 2019 | 467 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 1204 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 1183 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 502 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 499 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 68 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 978 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 231 | 0.030 |
Why?
|
| Hemangioma, Cavernous | 1 | 2014 | 27 | 0.030 |
Why?
|
| Prostate | 1 | 2020 | 1088 | 0.030 |
Why?
|
| Capecitabine | 1 | 2015 | 388 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2014 | 418 | 0.030 |
Why?
|
| Communication | 1 | 2021 | 876 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1987 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 395 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 929 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 702 | 0.030 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2012 | 16 | 0.030 |
Why?
|
| Spinal Curvatures | 1 | 2012 | 4 | 0.030 |
Why?
|
| Ileus | 1 | 2012 | 27 | 0.030 |
Why?
|
| Child | 2 | 2015 | 29154 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2008 | 16273 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2292 | 0.020 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 111 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 4892 | 0.020 |
Why?
|
| Pancreas | 1 | 2015 | 718 | 0.020 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 144 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2012 | 201 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2803 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2012 | 267 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3719 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2012 | 300 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 2864 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1546 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 793 | 0.020 |
Why?
|
| Disease Progression | 1 | 2020 | 6682 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 7548 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3230 | 0.020 |
Why?
|
| Neutropenia | 1 | 2012 | 968 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 1904 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 698 | 0.020 |
Why?
|
| Animals | 3 | 2020 | 59536 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2012 | 574 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 1248 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 2967 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 34495 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 11965 | 0.010 |
Why?
|